To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Transgene Announces Opening of First Clinical Site for its Phase II Trial of TG4040 for the Treatment of Chronic Hepatitis C
13-07-2010: Transgene S.A. announced the opening of the first clinical site for the phase II trial (named HCVac) of TG4040 (MVA-HCV) for the treatment of naïve genotype 1 hepatitis C infected patients in combination with standard of care (Pegylated-Interferon Alpha and Ribavarin).
HCVac is a phase II randomized, open-label, multi-site, international study that will enrol 140 patients chronically infected with HCV genotype 1 and who have not been previously treated for their infection. Forty clinical sites across seven countries in Europe, the United States and Israel will participate in the study.
HCVac has three arms: one control arm using standard of care alone and two experimental arms evaluating TG4040 at two different schedules of administration in combination with standard of care. In both experimental arms, TG4040 will be administered by subcutaneous injection at a dose of 107 pfu. The schedule of administration will consist of 6 injections in the first arm and 13 for the second arm.
The primary objective of HCVac is to evaluate the efficacy of TG4040, in combination with standard of care, as measured by the proportion of patients who achieve complete Early Virologic Response (cEVR). cEVR is defined as HCV RNA (ribonucleic acid) which is undetectable after 12 weeks of treatment.
The secondary objectives of the trial are: determine the effects on viral load over-time and up to 24 weeks after stopping therapy; determine the immunogenicity of TG4040 and identify molecular biomarkers related to TG4040 efficacy in combination with standard of care.
First results of the HCVac clinical trial are expected around the third quarter of 2011.
This is where you can add this news to your personal favourites
- 1Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 2Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 3Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 4Researchers divide enzyme to conquer genetic puzzle
- 5Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
- 6Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 7Sanofi-aventis to acquire Oenobiol
- 8Pharmexa enters into an agreement regarding GV1001 with the Korean company KAEL Co. Ltd
- 9DSM Sinochem Pharmaceuticals opens new 6-APA intermediate plant in China
- 10Pharmsynthez granted Orphan Drug Designation for Virexxa in the US
- History of analytical measuring technology in Jena
- Malvern Instruments announces global agreement with Proveris Scientific
- Analytik Jena to develop products for sepsis diagnostics
- analytica Vietnam 2013 – Platform for innovations
- Promega and BASF develop alternative method on identifying allergenic substances
- Novasep appoints Udo Steinhauer as fine chemicals market director
- Hybrid material for controlled drug delivery
- The adult generations of today are less healthy than their counterparts of previous generations
- Social bees mark dangerous flowers with chemical signals
- Trophos announces positive interim review in pivotal study of olesoxime in Spinal Muscular Atrophy